Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03898856 · ClinicalTrials.gov registry record · Phase 4
Yield of Diagnostic Tests and Effects of Crofelemer for Chronic Idiopathic Diarrhea In Non-HIV Patients
A Phase 4 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 4
- Development phase
- 93
- Enrollment target
NCT03898856 is a Phase 4 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 93 participants.
The verdict
NCT03898856, a Phase 4 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 93 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness of the drug Crofelemer in the treatment of non-HIV patients with chronic idiopathic diarrhea; to determine the prevalence of identifiable causes of chronic diarrhea in a non-HIV patients; to assess the diagnostic yield, in terms of identification of treatable etiologies, of commercially available diagnostic evaluations in adult, non-HIV patients with chronic idiopathic diarrhea, that is, evaluate which tests, among the standard diagnostic tests commonly conducted as part of the evaluation of chronic idiopathic diarrhea, are most likely to identify a treatable cause of the diarrhea; and to analyze the relationship between chronic idiopathic diarrhea and health-related quality of life and assess the impact of crofelemer treatment on health-related quality of life.
Interventions
- DRUG Crofelemer
- DIAGNOSTIC_TEST Diagnostic tests for cause of chronic diarrhea
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2019-04-01 |
| Est. Completion | 2025-01-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03898856
The ClinicalTrials.gov registry entry for NCT03898856 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Crofelemer is the first listed.
NCT03898856 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03898856 about?
NCT03898856 is a clinical study titled "Yield of Diagnostic Tests and Effects of Crofelemer for Chronic Idiopathic Diarrhea In Non-HIV Patients". The purpose of this study is to evaluate the effectiveness of the drug Crofelemer in the treatment of non-HIV patients with chronic idiopathic diarrhea; to determine the prevalence of identifiable causes of chronic diarrhea in a non-HIV patients; to assess the diagnostic yield, in terms of identific...
What is the current status of trial NCT03898856?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 93 participants. The study started on 2019-04-01. Estimated completion is 2025-01-30.
What interventions are being tested in trial NCT03898856?
The interventions under investigation include: Crofelemer (DRUG), Diagnostic tests for cause of chronic diarrhea (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03898856?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.